Seigle Jacquelyn L, Celotto Alicia M, Palladino Michael J
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA.
Genetics. 2008 Jun;179(2):855-62. doi: 10.1534/genetics.108.087551. Epub 2008 May 5.
Triose phosphate isomerase (TPI) deficiency glycolytic enzymopathy is a progressive neurodegenerative condition that remains poorly understood. The disease is caused exclusively by specific missense mutations affecting the TPI protein and clinically features hemolytic anemia, adult-onset neurological impairment, degeneration, and reduced longevity. TPI has a well-characterized role in glycolysis, catalyzing the isomerization of dihydroxyacetone phosphate (DHAP) to glyceraldehyde-3-phosphate (G3P); however, little is known mechanistically about the pathogenesis associated with specific recessive mutations that cause progressive neurodegeneration. Here, we describe key aspects of TPI pathogenesis identified using the TPI(sugarkill) mutation, a Drosophila model of human TPI deficiency. Specifically, we demonstrate that the mutant protein is expressed, capable of forming a homodimer, and is functional. However, the mutant protein is degraded by the 20S proteasome core leading to loss-of-function pathogenesis.
磷酸丙糖异构酶(TPI)缺乏性糖酵解酶病是一种进行性神经退行性疾病,目前人们对其了解甚少。该疾病完全由影响TPI蛋白的特定错义突变引起,临床特征为溶血性贫血、成人期神经功能损害、变性和寿命缩短。TPI在糖酵解中具有明确的作用,催化磷酸二羟丙酮(DHAP)异构化为3-磷酸甘油醛(G3P);然而,对于导致进行性神经退行性变的特定隐性突变相关的发病机制,从机制上了解甚少。在这里,我们描述了使用人类TPI缺乏症的果蝇模型TPI(sugarkill)突变鉴定出的TPI发病机制的关键方面。具体而言,我们证明突变蛋白能够表达、形成同二聚体且具有功能。然而,突变蛋白被20S蛋白酶体核心降解,导致功能丧失性发病机制。